Hexima Limited announced that a European patent covering the use of pezadeftide for the treatment of onychomycosis will be granted on 14 July 2021. The patent (#3209319) is described as "A Method of Treatment" and provides broad protection covering the therapeutic use of pezadeftide, as well as topical formulations containing pezadeftide, for the treatment of onychomycosis. The patent provides protection until 2035 and Hexima also expects to benefit from up to an additional five years of market exclusivity through the supplementary patent certification available for medicinal products in member states of the European Union. The award of this European patent further strengthens Hexima's patent portfolio which includes similar granted patents in the United States, Japan, Singapore and Australia. Hexima continues to pursue further patent filings in these and other jurisdictions; most recently receiving notification of the grant of "A Method of Treatment" patent (#382906) in Mexico.